Timothy C. Stonesifer, serving as a director for Insulet Corp (NASDAQ:PODD), completed a substantial acquisition of company stock on June 3, 2026. The transaction involved the purchase of 2,790 shares at a per-share price of $143.51, totaling $400,392. Following this acquisition, Mr. Stonesifer's direct holdings in Insulet Corp common stock stand at 9,041 shares.
The timing of this purchase is notable given the current market context for Insulet. The stock is trading near its 52-week low of $140.63, with the current share price at $146.41. This represents a significant decline of 55% over the past six months. Despite this price movement, Insulet maintains a market capitalization of $10.15 billion and holds a financial health score of 3.18, categorized as "GREAT". Analysis suggests the stock may be undervalued at current levels, placing it among opportunities on the Most Undervalued list.
Insulet has recently announced enhancements to its Omnipod 5 Automated Insulin Delivery System, following FDA clearance in December 2025. The updated algorithm introduces a 100 mg/dL target glucose option, expanding available settings and demonstrating improved median time in range for both type 1 and type 2 diabetes patients. However, the company also issued a voluntary medical device correction for approximately 7 million Omnipod insulin pods due to a manufacturing defect that could cause insulin leakage. This recall affects specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros pods distributed in the U.S. and international markets.
Despite the recall, Benchmark maintained a Buy rating with a $250 price target on Insulet shares. William Blair initiated coverage on Insulet with an Outperform rating, noting that the stock trades at a lower multiple compared to peers, despite faster sales growth. These developments highlight significant investor interest and concerns surrounding Insulet’s product line and market performance.